Adc Therapeutics Sa Stock Performance
| ADCT Stock | USD 3.03 0.08 2.57% |
ADC Therapeutics holds a performance score of 17 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of 1.34, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ADC Therapeutics will likely underperform. Use ADC Therapeutics coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to analyze future returns on ADC Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ADC Therapeutics SA are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental indicators, ADC Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.57) | Five Day Return (2.26) | Year To Date Return 51.5 | Ten Year Return (89.78) | All Time Return (89.78) |
1 | Disposition of 26758 shares by Mallik Ameet of ADC Therapeutics at 1.29 subject to Rule 16b-3 | 05/06/2025 |
2 | ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update ... | 05/14/2025 |
3 | Insider Trading | 06/03/2025 |
4 | ADC Therapeutics announces updated data from LOTIS-7 trial ADCT | 06/12/2025 |
5 | ADC Therapeutics Secures 100M in PIPE Financing to Boost ZYNLONTA Development | 06/13/2025 |
6 | ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in RR Marginal Zone Lymphoma Presented at 18th International Conference on Maligna... | 06/16/2025 |
7 | ADC Therapeutics Price Target Lowered by RBC Capital ADCT Stock News | 06/20/2025 |
8 | The 900 Billion Question Who Will Deliver the Next Cancer Breakthrough | 06/26/2025 |
9 | ADC Therapeutics files to sell 27.73M common shares by selling shareholders | 06/30/2025 |
10 | ADC Therapeutics Shares Down 4.2 percent - Whats Next - MarketBeat | 07/15/2025 |
| Begin Period Cash Flow | 278.6 M | |
| Total Cashflows From Investing Activities | -867 K |
ADC Therapeutics Relative Risk vs. Return Landscape
If you would invest 123.00 in ADC Therapeutics SA on April 20, 2025 and sell it today you would earn a total of 180.00 from holding ADC Therapeutics SA or generate 146.34% return on investment over 90 days. ADC Therapeutics SA is currently generating 1.7383% in daily expected returns and assumes 7.8177% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than ADC, and 65% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ADC Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADC Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ADC Therapeutics SA, and traders can use it to determine the average amount a ADC Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2224
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ADCT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.82 actual daily | 70 70% of assets are less volatile |
Expected Return
| 1.74 actual daily | 35 65% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average ADC Therapeutics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ADC Therapeutics by adding it to a well-diversified portfolio.
ADC Therapeutics Fundamentals Growth
ADC Stock prices reflect investors' perceptions of the future prospects and financial health of ADC Therapeutics, and ADC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ADC Stock performance.
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.98) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 268.55 M | ||||
| Shares Outstanding | 112.26 M | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 4.49 X | ||||
| Revenue | 69.28 M | ||||
| Gross Profit | (39.32 M) | ||||
| EBITDA | (103.71 M) | ||||
| Net Income | (157.85 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 123 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (2.40) X | ||||
| Cash Flow From Operations | (123.83 M) | ||||
| Earnings Per Share | (1.42) X | ||||
| Market Capitalization | 340.15 M | ||||
| Total Asset | 321.98 M | ||||
| Retained Earnings | (1.49 B) | ||||
| Working Capital | 226.92 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
About ADC Therapeutics Performance
Assessing ADC Therapeutics' fundamental ratios provides investors with valuable insights into ADC Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ADC Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.1 K | 856 | |
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.54) | (0.57) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | 0.78 | 0.82 |
Things to note about ADC Therapeutics performance evaluation
Checking the ongoing alerts about ADC Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ADC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ADC Therapeutics is way too risky over 90 days horizon | |
| ADC Therapeutics appears to be risky and price may revert if volatility continues | |
| ADC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 69.28 M. Net Loss for the year was (157.85 M) with loss before overhead, payroll, taxes, and interest of (39.32 M). | |
| ADC Therapeutics SA currently holds about 376.78 M in cash with (123.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 68.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: ADC Therapeutics Shares Down 4.2 percent - Whats Next - MarketBeat |
- Analyzing ADC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ADC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ADC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ADC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ADC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ADC Therapeutics' stock. These opinions can provide insight into ADC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.